Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910543 · ClinicalTrials.gov registry record · Phase 1
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03910543 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 15 participants.
The verdict
NCT03910543, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.
Interventions
- DRUG Tofacitinib 5 mg twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03910543
The ClinicalTrials.gov registry entry for NCT03910543 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib 5 mg twice daily is the first listed.
NCT03910543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03910543 about?
NCT03910543 is a clinical study titled "Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare". To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.
What is the current status of trial NCT03910543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-04-11. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT03910543?
The interventions under investigation include: Tofacitinib 5 mg twice daily (DRUG).
Who is sponsoring clinical trial NCT03910543?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.